Schneider Oliveira M, Flávia Furian A, Freire Royes L F, Rechia Fighera M, de Carvalho Myskiw J, Gindri Fiorenza N, Mello C F
Department of Physiology, Center of Health Sciences, Federal University of Santa Maria, 97105-900 Santa Maria, RS, Brazil.
Neuroscience. 2004;128(4):721-8. doi: 10.1016/j.neuroscience.2004.07.012.
Ascorbate is an antioxidant vitamin that is found in high concentrations in the brain which seems to have neuroprotective properties in some experimental models of excitotoxic neurological disorders, including convulsive behavior and reactive species-related damage. In this study we tested whether ascorbate (30, 100 or 300 mg/kg, i.p.) protects against the convulsions, protein carbonylation and inhibition of Na(+),K(+)-ATPase activity induced by pentylenetetrazol (PTZ; 1.8 micromol/striatum), a classical convulsant agent that has been fairly used for the study of epilepsy and screening of new compounds with antiepileptic activity. The intrastriatal injection of PTZ caused convulsive behavior in a dose-dependent manner and an increase in the total protein carbonyl content of the injected striatum. However, duration of PTZ-induced convulsive episodes did not correlate with protein carbonyl content of the injected striatum. Ascorbate, at high doses (300 mg/kg), protected against PTZ-induced convulsions, protein carbonylation and inhibition of Na(+),K(+)-ATPase activity in the rat striatum, further suggesting a anticonvulsant and neuroprotective role for this vitamin. Conversely, intermediate doses of ascorbate (100 mg/kg) potentiated the duration of the convulsive episodes, but had no additive effects on protein carbonylation or Na(+),K(+)-ATPase activity inhibition induced by PTZ. Low doses of ascorbate (30 mg/kg) prevented PTZ-induced increase of total striatal carbonyl protein content, but did not alter PTZ-induced convulsions and Na(+),K(+)-ATPase activity inhibition. Collectively, these data indicate that the anticonvulsant activity of ascorbate is not related to its antioxidant action and support a dual role for this compound as a neuroprotective agent, since while it protects against PTZ-induced cellular oxidative damage, it has a biphasic effect on PTZ-induced convulsions.
抗坏血酸是一种抗氧化维生素,在大脑中含量很高,在某些兴奋性毒性神经疾病的实验模型中似乎具有神经保护特性,包括惊厥行为和与活性物质相关的损伤。在本研究中,我们测试了抗坏血酸(30、100或300mg/kg,腹腔注射)是否能预防由戊四氮(PTZ;1.8μmol/纹状体)诱导的惊厥、蛋白质羰基化以及Na(+)、K(+)-ATP酶活性抑制,戊四氮是一种经典的惊厥剂,已被广泛用于癫痫研究和抗癫痫活性新化合物的筛选。纹状体内注射PTZ以剂量依赖的方式引起惊厥行为,并导致注射纹状体中总蛋白质羰基含量增加。然而,PTZ诱导的惊厥发作持续时间与注射纹状体的蛋白质羰基含量无关。高剂量(300mg/kg)的抗坏血酸可预防大鼠纹状体中PTZ诱导的惊厥、蛋白质羰基化以及Na(+)、K(+)-ATP酶活性抑制,进一步表明该维生素具有抗惊厥和神经保护作用。相反,中等剂量的抗坏血酸(100mg/kg)可延长惊厥发作的持续时间,但对PTZ诱导的蛋白质羰基化或Na(+)、K(+)-ATP酶活性抑制没有叠加作用。低剂量的抗坏血酸(30mg/kg)可预防PTZ诱导的纹状体总羰基蛋白含量增加,但不会改变PTZ诱导的惊厥和Na(+)、K(+)-ATP酶活性抑制。总体而言,这些数据表明抗坏血酸的抗惊厥活性与其抗氧化作用无关,并支持该化合物作为神经保护剂的双重作用,因为它既能预防PTZ诱导的细胞氧化损伤,又对PTZ诱导的惊厥有双相作用。